Shannon Ritter

Long-term effects of fingolimod in multiple sclerosis

Ludwig Kappos, Paul O’Connor, Ernst‐Wilhelm Radue et al. · Neurology · 2015 · 187 citations · Full text

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study

Jeffrey A. Cohen, Bhupendra Khatri, Frederik Barkhof et al. · Journal of Neurology Neurosurgery & Psychiatry · 2015 · 162 citations · Full text

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

Ludwig Kappos, Jeffrey A. Cohen, William Collins et al. · Multiple Sclerosis and Related Disorders · 2014 · 117 citations

Integrated Analysis, Disease Progression, Safety Findings +10

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study

Patricia Pozo‐Rosich, Christian Lucas, D. P. Watson et al. · Pain and Therapy · 2021 · 46 citations · Full text

Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Bruce Cree, Douglas L. Arnold, Robert J. Fox et al. · Multiple Sclerosis Journal · 2022 · 44 citations · Full text